BCL2 and prostate cancer: Similarly to the present results, Sensintaffar et al showed that siRNA-induced XIAP knockdown did not affect T24 BCa cell viability 72 and 96 h after treatment (34), neither did BCL2 inhibition in prostate cancer cell lines induce phenotypic changes (35).